Aurora cannabis files full year results and announces fiscal 2025 fourth quarter

Nasdaq | tsx: acb achieves record annual global medical cannabis net revenue 1 of $244.4 million, representing 39% yoy growth delivers record adjusted ebitda 1  of $49.7 million, representing 261% yoy growth generates annual positive free cash flow 1 of $9.9 million sustains strong balance sheet with ~$185.3 million of cash and debt-free cannabis business 2 edmonton, ab , june 18, 2025 /prnewswire/ - aurora cannabis inc. (the "company" or "aurora") (nasdaq: acb) (tsx: acb), a leading canada-based global medical cannabis company, today announced its financial and operational results for the fourth quarter and fiscal year 2025 periods ending march 31, 2025. "we are pleased to report an exceptional year to our shareholders, highlighted by record annual global medical net revenue1, adjusted ebitda1, and positive free cash flow1.
ACB Ratings Summary
ACB Quant Ranking